(Q38089433)

28 August 2017

Drug testing in mouse models of tuberculosis and nontuberculous mycobacterial infections (English)

1 reference

28 August 2017

1 reference

Boris V Nikonenko

1

1 reference

PubMed ID

23491715

28 August 2017

Alexander S Apt

series ordinal

2

1 reference

28 August 2017

11 March 2013

1 reference

28 August 2017

1 reference

28 August 2017

93

1 reference

28 August 2017

285-290

1 reference

28 August 2017

3

1 reference

Lessons from experimental Mycobacterium tuberculosis infections

28 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.02.010

Progression of chronic pulmonary tuberculosis in mice aerogenically infected with virulent Mycobacterium tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.02.010

Characterization of the tuberculous granuloma in murine and human lungs: cellular composition and relative tissue oxygen tension

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.02.010

Are mouse models of human mycobacterial diseases relevant? Genetics says: 'yes!'

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.02.010

Man and mouse TB: contradictions and solutions.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.02.010

Animal models of tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.02.010

Identification of new diamine scaffolds with activity against Mycobacterium tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.02.010

Rapid in vivo screening of experimental drugs for tuberculosis using gamma interferon gene-disrupted mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.02.010

Preclinical testing of the nitroimidazopyran PA-824 for activity against Mycobacterium tuberculosis in a series of in vitro and in vivo models

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.02.010

OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.02.010

Rapid, simple in vivo screen for new drugs active against Mycobacterium tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.02.010

Bactericidal activity of the nitroimidazopyran PA-824 in a murine model of tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.02.010

In vitro and in vivo activities of gatifloxacin against Mycobacterium tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.02.010

A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.02.010

Gatifloxacin and ethionamide as the foundation for therapy of tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.02.010

Antituberculosis activity of once-weekly rifapentine-containing regimens in mice. Long-term effectiveness with 6- and 8-month treatment regimens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.02.010

Antagonism between isoniazid and the combination pyrazinamide-rifampin against tuberculosis infection in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.02.010

Pharmacodynamics and pharmacokinetics of SQ109, a new diamine-based antitubercular drug

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.02.010

Evaluation of rifapentine in long-term treatment regimens for tuberculosis in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.02.010

Combinations of R207910 with drugs used to treat multidrug-resistant tuberculosis have the potential to shorten treatment duration

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.02.010

Anti-tuberculosis drug therapy in mice of different inbred strains

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.02.010

Drug therapy of experimental tuberculosis (TB): improved outcome by combining SQ109, a new diamine antibiotic, with existing TB drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.02.010

Activity of SQ641, a capuramycin analog, in a murine model of tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.02.010

Preclinical study of new TB drugs and drug combinations in mouse models

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.02.010

Identification of a new antitubercular drug candidate, SQ109, from a combinatorial library of 1,2-ethylenediamines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.02.010

Sterilizing activity of second-line regimens containing TMC207 in a murine model of tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.02.010

Pharmacokinetics-pharmacodynamics of rifampin in an aerosol infection model of tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.02.010

Isoniazid pharmacokinetics-pharmacodynamics in an aerosol infection model of tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.02.010

Combination chemotherapy with the nitroimidazopyran PA-824 and first-line drugs in a murine model of tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.02.010

Rifapentine, moxifloxacin, or DNA vaccine improves treatment of latent tuberculosis in a mouse model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.02.010

Moxifloxacin-containing Regimen Greatly Reduces Time to Culture Conversion in Murine Tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.02.010

Cellular and genetic mechanisms underlying susceptibility of animal models to tuberculosis infection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.02.010

Search for new drugs for treatment of tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.02.010

Synergistic activity of R207910 combined with pyrazinamide against murine tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.02.010

Bactericidal activity of increasing daily and weekly doses of moxifloxacin in murine tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.02.010

Bactericidal potencies of new regimens are not predictive of their sterilizing potencies in a murine model of tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.02.010

Direct comparison of low-dose and Cornell-like models of chronic and reactivation tuberculosis in genetically susceptible I/St and resistant B6 mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.02.010

Sterilizing activity of R207910 (TMC207)-containing regimens in the murine model of tuberculosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.02.010

Host genetics of mycobacterial diseases in mice and men: forward genetic studies of BCG-osis and tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.02.010

Interactions between antiretroviral agents and those used to treat tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.02.010

Paradoxically elevated efavirenz concentrations in HIV/tuberculosis- coinfected patients with CYP2B6 516TT genotype on rifampin-containing antituberculous therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.02.010

The pharmacogenetics of NAT2 enzyme maturation in perinatally HIV exposed infants receiving isoniazid

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.02.010

The clinical relevance of Mycobacterial pharmacogenetics.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.02.010

Pharmacogenomics of anti-TB drugs-related hepatotoxicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.02.010

Treatment of tuberculosis with rifamycin-containing regimens in immune-deficient mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.02.010

Mouse model of necrotic tuberculosis granulomas develops hypoxic lesions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.02.010

Evaluation of a mouse model of necrotic granuloma formation using C3HeB/FeJ mice for testing of drugs against Mycobacterium tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.02.010

Host genetics in granuloma formation: human-like lung pathology in mice with reciprocal genetic susceptibility to M. tuberculosis and M. avium

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.02.010

A human-like TB in genetically susceptible mice followed by the true dormancy in a Cornell-like model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.02.010

Development of new vaccines and drugs for TB: limitations and potential strategic errors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.02.010

Fluoroquinolone-containing third-line regimen against Mycobacterium tuberculosis in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.02.010

Experimental short-course preventive therapy of tuberculosis with rifampin and pyrazinamide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.02.010

Effects of protein calorie malnutrition on tuberculosis in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.02.010

Bactericidal activities of R207910 and other newer antimicrobial agents against Mycobacterium leprae in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.02.010

Biology of the mycobacterioses. Experimental models for studying leprosy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.02.010

The diarylquinoline R207910 is bactericidal against Mycobacterium leprae in mice at low dose and administered intermittently

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.02.010

Mycobacterial infections caused by nontuberculous mycobacteria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.02.010

Mycobacterium avium-triggered diseases: pathogenomics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.02.010

Activity of ABT-773 against Mycobacterium avium complex in the beige mouse model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.02.010

Beige mouse model for Mycobacterium avium complex disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.02.010

Effectiveness of various antimicrobial agents against Mycobacterium avium complex in the beige mouse model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.02.010

Pharmacokinetics, toxicity, and efficacy of liposomal capreomycin in disseminated Mycobacterium avium beige mouse model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.02.010

Alphabeta T cell receptor-positive cells and interferon-gamma, but not inducible nitric oxide synthase, are critical for granuloma necrosis in a mouse model of mycobacteria-induced pulmonary immunopathology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.02.010

I/St mice hypersusceptible to Mycobacterium tuberculosis are resistant to M. avium

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.02.010

IL-10 underlies distinct susceptibility of BALB/c and C57BL/6 mice to Mycobacterium avium infection and influences efficacy of antibiotic therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.02.010

Activity of azithromycin against Mycobacterium avium infection in beige mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.02.010

Activity of rifapentine against Mycobacterium avium infection in beige mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.02.010

How effective is KRM-1648 in treatment of disseminated Mycobacterium avium complex infections in beige mice?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.02.010

Mycobacterium avium subsp. paratuberculosis in Veterinary Medicine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.02.010

Mycobacterium avium subspecies paratuberculosis and Crohn's disease: a systematic review and meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.02.010

Mycobacterium avium paratuberculosis invades human small-intestinal goblet cells and elicits inflammation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.02.010

Mycobacteria in Crohn’s disease: how innate immune deficiency may result in chronic inflammation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.02.010

Expression library immunization confers protection against Mycobacterium avium subsp. paratuberculosis infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.02.010

Development of luminescent Mycobacterium avium subsp. paratuberculosis for rapid screening of vaccine candidates in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.02.010

Anti-mycobacterial therapy in Crohn's disease heals mucosa with longitudinal scars

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.02.010

Treatment of severe Crohn's disease using antimycobacterial triple therapy--approaching a cure?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.02.010

Long‐Term Antibiotic Treatment for Crohn's Disease: Systematic Review and Meta‐Analysis of Placebo‐Controlled Trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.02.010

Two-year combination antibiotic therapy with clarithromycin, rifabutin, and clofazimine for Crohn's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.02.010

Use of rifabutin in treatment of systemic Mycobacterium paratuberculosis infection in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.02.010

Importance of T cells, gamma interferon, and tumor necrosis factor in immune control of the rapid grower Mycobacterium abscessus in C57BL/6 mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.02.010

Animal model of Mycobacterium abscessus lung infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.02.010

Host immune response to rapidly growing mycobacteria, an emerging cause of chronic lung disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.02.010

Comparative studies evaluating mouse models used for efficacy testing of experimental drugs against Mycobacterium tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.02.010

Low-dose aerosol infection model for testing drugs for efficacy against Mycobacterium tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.02.010

inferred from DOI database lookup

7 January 2021

based on heuristic

Infection of SCID mice with Mycobacterium leprae and control with antigen-activated "immune" human peripheral blood mononuclear cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.02.010

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.TUBE.2013.02.010

1 reference

28 August 2017

1 reference

PubMed ID

23491715